The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer
Open accessAbstract
PURPOSE: This phase I clinical trial evaluated the safety, tolerability, and pharmacokinetics of high-dose intravenous (i.v.) ascorbic acid as a monotherapy in patients with advanced solid tumors refractory to standard therapy. METHODS: Five cohorts of three patients received i.v. ascorbic acid administered at 1 g/min for 4 consecutive days/week for 4 weeks, starting at 30 g/m² in the first cohort. For subsequent cohorts, dose was increased by 20 g/m² until a maximum tolerated dose was found. RESULTS: Ascorbic acid was eliminated by simple first-order kinetics. Half-life and clearance values were similar for all patients of all cohorts (2.0 ± 0.6 h, 21 ± 5 dL/h m², respectively). C(max) and AUC values increased proportionately with dose between 0 and 70 g/m², but appeared to reach maximal values at 70 g/m² (49 mM and 220 h mM, respectively). Doses of 70, 90, and 110 g/m² maintained levels at or above 10-20 mM for 5-6 h. All doses were well tolerated. No patient demonstrated an objective antitumor response. CONCLUSIONS: Ascorbic acid administered i.v. at 1 g/min for 4 consecutive days/week for 4 weeks produced up to 49 mM ascorbic acid in patient's blood and was well tolerated. The recommended dose for future studies is 70-80 g/m².
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524 · cited 1×
“a g/kg 9 37 = g/m(2) [37] Cancer Chemother Pharmacol”
BackgroundChen, Q., Espey, M. G., Krishna, M. C., Mitchell, J. B., Corpe, C. P., Buettner, G. R., Shacter, E., & Levine, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506390102 · Cited by 1,075
Kennedy, C. O. (1971) · British Homeopathic Journal · doi:10.1016/s0007-0785(71)80027-3 · Cited by 974
Cameron, E., & Pauling, L. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.10.3685 · Cited by 710
Moertel, C. G., Fleming, T. R., Creagan, E. T., Rubin, J., O'Connell, M. J., & Ames, M. M. (1985) · New England Journal of Medicine · doi:10.1056/nejm198501173120301 · Cited by 637 · cited 1×
“However, more recent double-blind, placebo-controlled studies conducted at the Mayo Clinic have shown that oral administration of ascorbic acid provides no consistent benefit to cancer patients [18, 19].”
BackgroundCreagan, E. T., Moertel, C. G., O'Fallon, J. R., Schutt, A. J., O'Connell, M. J., Rubin, J., & Frytak, S. (1979) · New England Journal of Medicine · doi:10.1056/nejm197909273011303 · Cited by 584
Cocks, K., King, M. T., Velikova, G., de Castro, G., Martyn St-James, M., Fayers, P. M., & Brown, J. M. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.02.059 · Cited by 552
Groenvold, M., Klee, M. C., Sprangers, M. A. G., & Aaronson, N. K. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(96)00428-3 · Cited by 482
Phase I clinical trial of i.v. ascorbic acid in advanced malignancy
Hoffer, L. J., Levine, M., Assouline, S., Melnychuk, D., Padayatty, S. J., Rosadiuk, K., Rousseau, C., Robitaille, L., & Miller, W. H. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn377 · Cited by 375
Cited by
Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH
Yun, J., Mullarky, E., Lu, C., Bosch, K. N., Kavalier, A., Rivera, K., Roper, J., Chio, I. I. C., Giannopoulou, E. G., Rago, C., et al. (2015) · Science · doi:10.1126/science.aaa5004 · Cited by 913
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock
Marik, P. E., Khangoora, V., Rivera, R., Hooper, M. H., & Catravas, J. (2017) · Chest · doi:10.1016/j.chest.2016.11.036 · Cited by 887
The Pharmacokinetics of Vitamin C
Lykkesfeldt, J., & Tveden-Nyborg, P. (2019) · Nutrients · doi:10.3390/nu11102412 · Cited by 344
“Relationship between infusion dose of vitC and plasma Cmax in cancer patients as compiled from [13,75].”
BackgroundMethodTET (Ten-eleven translocation) family proteins: structure, biological functions and applications
Zhang, X., Zhang, Y., Wang, C., & Wang, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01537-x · Cited by 273
Iron and thiol redox signaling in cancer: an exquisite balance to escape ferroptosis
Toyokuni, S., Ito, F., Yamashita, K., Okazaki, Y., & Akatsuka, S. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.04.024 · Cited by 252
Vitamin C in stem cell reprogramming and cancer
Cimmino, L., Neel, B. G., & Aifantis, I. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.04.001 · Cited by 197
Potential Mechanisms of Action for Vitamin C in Cancer: Reviewing the Evidence
Vissers, M. C. M., & Das, A. B. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00809 · Cited by 188
“While there are suggestions of a clinical benefit from these vitamin C infusions (Hoffer et al., 2008, 2015; Stephenson et al., 2013; Welsh et al., 2013), it remains a challenge to determine whether this is due to an ascorbate-mediated prooxidant effect.”
InfluentialThe role of vitamin C in the treatment of pain: new insights
Carr, A. C., & McCall, C. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1179-7 · Cited by 160
“However, it should be noted that because vitamin C has a short half-life in plasma of approximately 2 h [90], the high (millimolar) plasma concentrations provided by intravenous administration are relatively transient.”
BackgroundIntravenous Vitamin C for Cancer Therapy – Identifying the Current Gaps in Our Knowledge
Carr, A. C., & Cook, J. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01182 · Cited by 133
Intravenous Vitamin C and Cancer: A Systematic Review
Fritz, H., Flower, G., Weeks, L., Cooley, K., Callachan, M., McGowan, J., Skidmore, B., Kirchner, L., & Seely, D. (2014) · Integrative Cancer Therapies · doi:10.1177/1534735414534463 · Cited by 124
“Stephenson et al found that QOL as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Cancer (EORTCQLQ-C30) questionnaire remained stable for the first 2 weeks among patients receiving IVC; at weeks 3 and 4, QOL seemed to improve for the small number of patients wh…”
BackgroundMethodInfluentialUpregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells
Shenoy, N., Bhagat, T., Nieves, E., Stenson, M., Lawson, J., Choudhary, G. S., Habermann, T., Nowakowski, G., Singh, R., Wu, X., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.65 · Cited by 111
Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials
Nauman, G., Gray, J. C., Parkinson, R., Levine, M., & Paller, C. J. (2018) · Antioxidants · doi:10.3390/antiox7070089 · Cited by 107
Intravenous vitamin C in the supportive care of cancer patients: A review and rational approach
Klimant, E., Wright, H., Rubin, D., Seely, D., & Markman, M. (2018) · Current Oncology · doi:10.3747/co.25.3790 · Cited by 99
The effect of intravenous vitamin C on cancer- and chemotherapy-related fatigue and quality of life
Carr, A. C., Vissers, M. C. M., & Cook, J. S. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00283 · Cited by 104
Strategies to tackle RAS-mutated metastatic colorectal cancer
Patelli, G., Tosi, F., Amatu, A., Mauri, G., Curaba, A., Patanè, D. A., Pani, A., Scaglione, F., Siena, S., & Sartore-Bianchi, A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100156 · Cited by 86
Ma, E., Chen, P., Wilkins, H. M., Wang, T., Swerdlow, R. H., & Chen, Q. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.09.008 · Cited by 79
Campbell, E. J., Vissers, M. C. M., Wohlrab, C., Hicks, K. O., Strother, R. M., Bozonet, S. M., Robinson, B. A., & Dachs, G. U. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.08.027 · Cited by 67
Pharmacokinetic modeling of ascorbate diffusion through normal and tumor tissue
Kuiper, C., Vissers, M. C. M., & Hicks, K. O. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.09.023 · Cited by 45
The interplay between vitamin C and thyroid
Farasati Far, B., Behnoush, A. H., Ghondaghsaz, E., Habibi, M. A., & Khalaji, A. (2023) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.432 · Cited by 23
Metadata
- Authors
- Stephenson, C. M., Levin, R. D., Spector, T., & Lis, C. G.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2013-05-14
- Volume
- 72
- Issue
- 1
- Pages
- 139-146
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2160014667
- Cited by
- 264
- References
- 36
- FWCI
- 13.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.